Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Ferritinemia during type 1 Gaucher disease: mechanisms and progression under treatment.

Mekinian A, Stirnemann J, Belmatoug N, Heraoui D, Fantin B, Fain O, Charpentier A, Rose C.

Blood Cells Mol Dis. 2012 Jun 15;49(1):53-7. doi: 10.1016/j.bcmd.2012.04.002.

PMID:
22560483
2.

Velaglucerase alfa for the management of type 1 Gaucher disease.

Morris JL.

Clin Ther. 2012 Feb;34(2):259-71. doi: 10.1016/j.clinthera.2011.12.017. Review.

PMID:
22264444
3.

Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease.

Stirnemann J, Boutten A, Vincent C, Mekinian A, Heraoui D, Fantin B, Fain O, Mentré F, Belmatoug N.

Blood Cells Mol Dis. 2011 Jan 15;46(1):34-8. doi: 10.1016/j.bcmd.2010.10.014.

PMID:
21084203
4.

[Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].

Tóth J, Szücs FZ, Benkö K, Maródi L.

Orv Hetil. 2003 Apr 20;144(16):749-55. Hungarian.

PMID:
12778625
5.

Gaucher disease: outcome following total hip replacements and effect of enzyme replacement therapy in a cohort of UK patients.

Donaldson J, Khan WS, Tailor H, Hughes DA, Mehta AB, Maruthainar N.

Hip Int. 2011 Nov-Dec;21(6):665-71. doi: 10.5301/HIP.2011.8826.

PMID:
22101622
6.

Cessation of enzyme replacement therapy in Gaucher disease.

Grinzaid KA, Geller E, Hanna SL, Elsas LJ 2nd.

Genet Med. 2002 Nov-Dec;4(6):427-33.

PMID:
12509713
7.

[A retrospective study on enzyme replacement therapy in patients with Gaucher disease].

Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.

Zhonghua Er Ke Za Zhi. 2006 Sep;44(9):653-6. Chinese.

PMID:
17217655
8.
9.

The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.

Piran S, Roberts A, Patterson MA, Amato D.

Blood Cells Mol Dis. 2009 Nov-Dec;43(3):289-93. doi: 10.1016/j.bcmd.2009.08.002.

PMID:
19793665
10.

The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.

Charrow J, Dulisse B, Grabowski GA, Weinreb NJ.

Clin Genet. 2007 Mar;71(3):205-11.

PMID:
17309642
11.

Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.

van Dussen L, Hendriks EJ, Groener JE, Boot RG, Hollak CE, Aerts JM.

J Inherit Metab Dis. 2014 Nov;37(6):991-1001. doi: 10.1007/s10545-014-9711-x.

PMID:
24831585
12.

Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study.

Zimmermann A, Grigorescu-Sido P, Rossmann H, Lackner KJ, Drugan C, Al Khzouz C, Bucerzan S, Naşcu I, Zimmermann T, Leucuţa D, Weber MM.

J Inherit Metab Dis. 2013 May;36(3):555-63. doi: 10.1007/s10545-012-9529-3.

PMID:
22976766
13.
14.

Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: results from the NCS-LSD cohort study.

Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Hughes DA, Waldek S, Logan S.

J Inherit Metab Dis. 2014 Nov;37(6):953-60. doi: 10.1007/s10545-014-9680-0.

PMID:
24515873
15.

Iron metabolism in patients with anorexia nervosa: elevated serum hepcidin concentrations in the absence of inflammation.

Papillard-Marechal S, Sznajder M, Hurtado-Nedelec M, Alibay Y, Martin-Schmitt C, Dehoux M, Westerman M, Beaumont C, Chevallier B, Puy H, Stheneur C.

Am J Clin Nutr. 2012 Mar;95(3):548-54. doi: 10.3945/ajcn.111.025817.

16.

Biomarkers in Serbian patients with Gaucher disease.

Sumarac Z, Suvajdžić N, Ignjatović S, Majkić-Singh N, Janić D, Petakov M, Dorđević M, Mitrović M, Dajak M, Golubović M, Rodić P.

Clin Biochem. 2011 Aug;44(12):950-4. doi: 10.1016/j.clinbiochem.2011.05.016.

PMID:
21640089
17.

Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort study.

Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Waldek S, Hughes DA, Pastores GM, Logan S.

J Inherit Metab Dis. 2014 Nov;37(6):961-8. doi: 10.1007/s10545-014-9693-8.

PMID:
24638276
18.

Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.

Vigan M, Stirnemann J, Caillaud C, Froissart R, Boutten A, Fantin B, Belmatoug N, Mentré F.

Orphanet J Rare Dis. 2014 Jun 30;9:95. doi: 10.1186/1750-1172-9-95.

19.

Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.

Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN.

J Bone Miner Res. 2007 Jan;22(1):119-26.

20.

Serum ferritin levels are increased in patients with glomerular diseases and proteinuria.

Branten AJ, Swinkels DW, Klasen IS, Wetzels JF.

Nephrol Dial Transplant. 2004 Nov;19(11):2754-60.

Items per page

Supplemental Content

Support Center